These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19501260)

  • 1. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O; Heredia A; Gallo RC; Reitz M; Le N; Redfield RR
    Antiviral Res; 2009 Jul; 83(1):86-9. PubMed ID: 19501260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
    Heredia A; Latinovic O; Gallo RC; Melikyan G; Reitz M; Le N; Redfield RR
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20476-81. PubMed ID: 19075241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.
    Heredia A; Amoroso A; Davis C; Le N; Reardon E; Dominique JK; Klingebiel E; Gallo RC; Redfield RR
    Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10411-6. PubMed ID: 12915736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
    Yeni P; Lamarca A; Berger D; Cimoch P; Lazzarin A; Salvato P; Smaill FM; Teofilo E; Madison SJ; Nichols WG; Adkison KK; Bonny T; Millard J; McCarty D;
    HIV Med; 2009 Feb; 10(2):116-24. PubMed ID: 19200175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
    Pfaff JM; Wilen CB; Harrison JE; Demarest JF; Lee B; Doms RW; Tilton JC
    J Virol; 2010 Jul; 84(13):6505-14. PubMed ID: 20410277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances of CCR5 antagonists.
    Baba M
    Curr Opin HIV AIDS; 2006 Sep; 1(5):367-72. PubMed ID: 19372835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF; Sparks SS; Schell K; Shibayama S; McDanal CB; Fang L; Adkison KK; Shachoy-Clark A; Piscitelli SC
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
    Tilton JC; Amrine-Madsen H; Miamidian JL; Kitrinos KM; Pfaff J; Demarest JF; Ray N; Jeffrey JL; Labranche CC; Doms RW
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):13-24. PubMed ID: 20055594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H; Maeda K; Miyakawa T; Shibayama S; Matsuo M; Takaoka Y; Ito M; Koyanagi Y; Mitsuya H
    J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
    Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
    J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
    J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.
    Guan Y; Abdelwahab S; Kamin-Lewis R; DeVico AL; Lewis GK
    PLoS One; 2008; 3(10):e3481. PubMed ID: 18941536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.